Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

(2017) Roland Seiler et al.   EUROPEAN UROLOGY

Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification

(2017) Gottfrid Sjödahl et al.   JOURNAL OF PATHOLOGY

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

(2017) Nolan Priedigkeit et al.   JAMA Oncology

Tumor heterogeneity offibroblast growth factor receptor 3(FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment

(2016) D. Pouessel et al.   ANNALS OF ONCOLOGY

A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response

(2016) George Sflomos et al.   CANCER CELL

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

(2016) Floris H. Groenendijk et al.   EUROPEAN UROLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma

(2016) Mathilde B.H. Thomsen et al.   Molecular Oncology

Analysis of protein-coding genetic variation in 60,706 humans

(2016) Monkol Lek et al.   NATURE

Clonal evolution of chemotherapy-resistant urothelial carcinoma

(2016) Bishoy M Faltas et al.   NATURE GENETICS

COSMIC: somatic cancer genetics at high-resolution

(2016) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use

(2016) Vipulkumar Dadhania et al.   EBioMedicine

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

(2015) Elizabeth R. Plimack et al.   EUROPEAN UROLOGY

FGFR3 Expression in Primary Invasive Bladder Cancers and Matched Lymph Node Metastases

(2015) Rafal Turo et al.   JOURNAL OF UROLOGY

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma

(2015) Alexander S. Baras et al.   PLoS One

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Transforming Growth Factor β-Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression

(2014) Tom L. Stephen et al.   IMMUNITY

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

(2014) J. S. Damrauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

(2014) E. M. Van Allen et al.   Cancer Discovery

Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer

(2014) Iver Nordentoft et al.   Cell Reports

Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program

(2013) Kevin J. Cheung et al.   CELL

CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response

(2013) Roland Seiler et al.   MODERN PATHOLOGY

Inferring tumour purity and stromal and immune cell admixture from expression data

(2013) Kosuke Yoshihara et al.   Nature Communications

A Molecular Taxonomy for Urothelial Carcinoma

(2012) G. Sjodahl et al.   CLINICAL CANCER RESEARCH

The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation

(2012) Florencia Cano et al.   EMBO JOURNAL

Inhibition of T-cell activation by PIK3IP1

(2012) Marie C. DeFrances et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours

(2011) Achim Fleischmann et al.   EUROPEAN UROLOGY

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

(2011)   JOURNAL OF CLINICAL ONCOLOGY

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

(2010) A. Font et al.   ANNALS OF ONCOLOGY

Telomere-independent Rap1 is an IKK adaptor and regulates NF-κB-dependent gene expression

(2010) Hsiangling Teo et al.   NATURE CELL BIOLOGY

A method and server for predicting damaging missense mutations

(2010) Ivan A Adzhubei et al.   NATURE METHODS

HER2Overexpression and Amplification in Urothelial Carcinoma of the Bladder Is Associated WithMYCCoamplification in a Subset of Cases

(2008) Donna E. Hansel et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY